Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvomertinib vs traditional chemotherapy in pediatric Langerhans cell histiocytosis
ChiCTR2600127163Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of luvometinib in Langerhans cell histiocytosis (LCH) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective Response Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
luvometinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2600127163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127163.